IMTX Stock Forecast: Immatics NV Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.78
−2.86% on the day

The 9 Wall Street analysts covering Immatics NV hold a median 12-month price target of $15 — +159.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$906.0M
Ticker Nerd rank
22/ 100
Median analyst target
$15
Analysts covering
9
Revenue$9.1M+93.0% y/y
Operating income−$67.2M
Net income−$62.5M
Free cash flow−$61.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.5%
1M
−23.0%
YTD
−45.0%
1Y
−42.8%
From 52W high
−51.3%
From 52W low
0.0%
$6
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Immatics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
22/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
74
Value
70
Momentum
52
Accruals
46
Quality
26
Revisions
25
Growth
22
Issuance
13

Volatility (74): The share price has been relatively steady.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IMTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26IMTXHigh $21Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$12
Low
$15
Median
$21
High

The green dot is the last close — the median target sits +159.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026StifelInitiatesBuy$15
19 May 2026Chardan CapitalMaintainsBuy$25
28 Apr 2026TD CowenInitiatesBuy—
16 Mar 2026JefferiesAssumesBuy$18
24 Nov 2025Chardan CapitalMaintainsBuy—
19 Nov 2025MizuhoMaintainsOutperform—
18 Nov 2025GuggenheimMaintainsBuy—
18 Sept 2025GuggenheimInitiatesBuy—
28 May 2025Deutsche BankInitiatesBuy—
1 Apr 2025Cantor FitzgeraldReiteratesOverweight—
19 Nov 2024B of A SecuritiesMaintainsBuy—
7 Oct 2024Piper SandlerInitiatesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
5 Sept 2024Cantor FitzgeraldReiteratesOverweight—
16 May 2024MizuhoMaintainsBuy—
2 Nov 2023Cantor FitzgeraldInitiatesOverweight—
31 Mar 2023MizuhoInitiatesBuy—
23 Mar 2023Chardan CapitalMaintainsBuy—
10 Aug 2022Chardan CapitalMaintainsBuy—
3 June 2022SVB LeerinkMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMTX.

Market Radar

This page is one stock. Monday covers all of them.

IMTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IMTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Immatics NV returned −42.8% against +6.9% for the S&P 500, dividends included.

IMTX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26IMTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
20.3×

Cheaper than 8% of US stocks

Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−54.3%

Higher than 21% of US stocks

Return on assets
−28.9%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immatics NV has a market value of $906.0M and an enterprise value of $491.5M.

  • Revenue in the twelve months to 30 June 2026: $41.7M. The latest quarter grew 93.0% year on year.

  • Net income over the same four quarters: −$206.5M, a −495.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$209.6M.

  • Shares outstanding: 136.7M.

  • Immatics NV employs 721 people — $58K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

IMTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMTXImmatics NV$906.0M22
AKTSAktis Oncology, Inc.$892.7M2
LTGOLatigo Biotherapeutics, Inc.$822.1M1
CRVSCorvus Pharmaceuticals, Inc.$810.0M48
ODTXOdyssey Therapeutics, Inc.$800.1M1
BBTXBambusa Therapeutics, Inc.$796.2M0
SVRASavara, Inc.$939.9M28

Take a look at IMTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Immatics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IMTX

What is the IMTX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Immatics NV have a median 12-month price target of $15, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMTX stock a buy right now?

Of the 9 analysts covering Immatics NV, 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immatics NV 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMTX?

As at 21 Nov 2026, Immatics NV ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (74 of 100).

Will IMTX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +159.5% from the last close, and Ticker Nerd's factor model ranks Immatics NV 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMTX stock forecast for 2030?

No analyst covering Immatics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.

How has IMTX stock performed over the past year?

Immatics NV returned -42.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immatics NV do?

Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics.

Company

About Immatics NV.

Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics. Its current work centers on PRAME-targeted immunotherapy, a cancer-associated target used across multiple oncology applications. Immatics N.V. operates as a research-driven oncology company with a pipeline built around precision immunotherapy platforms and collaborations that support the development of next-generation cancer treatments. Headquartered in Tübingen, Germany, the company serves the broader biopharmaceutical market through its focus on novel therapies for patients with difficult-to-treat cancers.

CEO Dr. Harpreet Singh Ph.D. · 721 employees · Germany · https://www.immatics.com